Robert E. Conway - 13 May 2021 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Reporting relationship: Director, Chairman of the Board
Issuer ticker: ORKA
Reported as of: 13 May 2021
Net transaction value: +$31,947
SEC form: 4
Accepted by SEC: 13 May 2021, 17:00:43 UTC
Next SEC filing: 23 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ C. Jeffrey Dekker, Attorney-in-Fact

Key filing fact

Robert E. Conway filed Form 4 for ARCA biopharma, Inc. (ORKA) on 13 May 2021.

Key facts

This page summarizes Robert E. Conway's Form 4 filing for ARCA biopharma, Inc. (ORKA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 May 2021, 17:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$31,947.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABIO transaction

Common Stock

Purchase

Transaction value: $31,947
Shares: +10,000
Change %: +25%
Price: $3.19
Shares after: 50,000
Date: 12 May 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $3.18 to $3.20. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased at each separate price.